Loading…
Sarepta Therapeutics, Inc. is projected to rise to $25.82 by 2027, a +26% move from its current price of $20.52. SRPT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $19.87 | $20.52 | $21.20 | +0.02% |
| Jul 13 | $19.61 | $20.53 | $21.49 | +0.05% |
| Jul 14 | $19.41 | $20.53 | $21.72 | +0.07% |
| Jul 15 | $19.25 | $20.54 | $21.92 | +0.09% |
| Jul 16 | $19.11 | $20.54 | $22.09 | +0.11% |
| Jul 17 | $18.98 | $20.55 | $22.25 | +0.14% |
| Jul 18 | $18.86 | $20.55 | $22.39 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.86 | $20.55 | $22.39 | +0.16% |
| Week 2 | $18.23 | $20.59 | $23.24 | +0.32% |
| Week 3 | $17.77 | $20.62 | $23.92 | +0.48% |
| Week 4 | $17.39 | $20.65 | $24.52 | +0.64% |
| Week 5 | $17.07 | $20.68 | $25.06 | +0.80% |
| Week 6 | $16.79 | $20.72 | $25.56 | +0.96% |
| Week 7 | $16.54 | $20.75 | $26.04 | +1.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials.
It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta Therapeutics, Inc. (SRPT) is currently priced at $19.79, with a market capitalization of $2.09B and a rank of 2014. The stock sits in the Healthcare category. The current price sits near resistance at $19.79, with a 30-day price range of $16.19 to $24.19 and a bullish technical sentiment supported by RSI at 70.
Key moving averages are SMA50 at $18.02 and SMA200 at $19.72, with a standing support at $15.00 and a resistance at $19.79. The forecast shows an evolving path from a neutral stance in 2026 toward stronger upside in coming years, culminating in a 2050 average price well above today’s level. The projected path includes a long-run rise in average prices and rising ROI, reflecting potential upside over time.
A major floor 38.4% below — a decisive break under it would weaken the trend.
The nearest floor, 26.9% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 15.8% above — clearing it would confirm fresh momentum.
Key SRPT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SRPT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.73 | Buy | $19.47 | Buy |
| MA 10 | $18.80 | Buy | $18.92 | Buy |
| MA 20 | $17.60 | Buy | $18.21 | Buy |
| MA 50 | $17.97 | Buy | $18.13 | Buy |
| MA 100 | $18.67 | Buy | $18.86 | Buy |
| MA 200 | $19.74 | Buy | $23.72 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.13 | Neutral |
| Stoch RSI (14) | 50.07 | Neutral |
| CCI (20) | 67.43 | Neutral |
| Williams %R (14) | -34.89 | Info |
| MACD (12,26,9) | 0.37 | Buy |
| ROC (12) | 9.79 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 65.11 | Neutral |
| TRIX (15) | 0.23 | Buy |
| Awesome (5,34) | 2.57 | Buy |
| Ultimate (7,14,28) | 59.53 | Neutral |
| Momentum (10) | 2.93 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 20.42 | Buy |
| ADX (14) | 21.19 | Buy |
| ATR (14) | 0.57 | Info |
In the near term, the 30-day picture remains constructive with a bullish tilt. The stock trades with RSI around 70 and sits between the SMA50 of $18.02 and the SMA200 of $19.72, indicating a positive trend with a slight edge to the upside. The 30-day range runs from $16.19 to $24.19, providing a corridor within which the price may oscillate before a clearer directional move.
Support sits at $15.00, while resistance remains at $19.79, highlighting a foundational floor and a cap near current pricing.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.00 | $20.52 | $28.97 | 0% | Neutral | |
| $20.20 | $25.82 | $35.14 | +26% | Bullish | |
| $20.62 | $27.26 | $38.72 | +33% | Bullish | |
| $20.24 | $27.54 | $40.43 | +34% | Bullish | |
| $20.32 | $28.34 | $42.78 | +38% | Bullish | |
| $21.87 | $31.20 | $48.27 | +52% | Bullish | |
| $21.88 | $31.90 | $50.42 | +55% | Bullish | |
| $26.01 | $38.68 | $62.36 | +89% | Bullish | |
| $30.75 | $46.63 | $76.53 | +127% | Bullish | |
| $29.49 | $45.55 | $76.02 | +122% | Bullish | |
| $38.27 | $64.34 | $115.10 | +214% | Bullish | |
| $60.21 | $117.54 | $232.47 | +473% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.00 | $20.52 | $24.89 | +0.00% |
| August 2026 | $17.23 | $20.45 | $24.99 | -0.35% |
| September 2026 | $17.51 | $20.95 | $25.94 | +2.45% |
| October 2026 | $18.45 | $22.23 | $27.83 | +6.13% |
| November 2026 | $18.68 | $22.65 | $28.61 | +1.86% |
| December 2026 | $18.65 | $22.74 | $28.97 | +0.42% |
Click any year to see its month-by-month SRPT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect SRPT to range from $15.00 to $28.97 through 2026. The $20.52 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The SRPT price prediction for 2027 points to an average of $25.82 (low $20.20, high $35.14) — a potential gain of +26% on today's $20.52. Buyers look set to stay in control over this stretch.
In 2028, SRPT is projected to trade between $20.62 and $38.72, averaging $27.26 — a potential gain of +33% from today's $20.52. That is up +6% on the projected 2027 average. Momentum favours further upside here.
Sarepta Therapeutics, Inc.'s 2029 outlook centres on $27.54, within a $20.24 to $40.43 range. That is up +1% on the projected 2028 average. That marks a +34% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, SRPT could reach as high as $42.78, with a base case around $28.34 and support toward $20.32 — roughly +38% from $20.52. Momentum favours further upside here.
Expect SRPT to range from $21.87 to $48.27 through 2031. The $31.20 average target implies a +52% move from current prices. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The SRPT price prediction for 2032 points to an average of $31.90 (low $21.88, high $50.42) — a potential gain of +55% on today's $20.52. Momentum favours further upside here.
In 2033, SRPT is projected to trade between $26.01 and $62.36, averaging $38.68 — a potential gain of +89% from today's $20.52. That is up +21% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Sarepta Therapeutics, Inc.'s 2034 outlook centres on $46.63, within a $30.75 to $76.53 range. That is up +21% on the projected 2033 average. That marks a +127% change versus current levels. Momentum favours further upside here.
By 2035, SRPT could reach as high as $76.02, with a base case around $45.55 and support toward $29.49 — roughly +122% from $20.52. Buyers look set to stay in control over this stretch.
Expect SRPT to range from $38.27 to $115.10 through 2040. The $64.34 average target implies a +214% move from current prices. That is up +41% on the projected 2035 average. Momentum favours further upside here.
The SRPT price prediction for 2050 points to an average of $117.54 (low $60.21, high $232.47) — a potential gain of +473% on today's $20.52. Buyers look set to stay in control over this stretch.
Investing $1,000 in SRPT today (≈ 48.732943 SRPT) could be worth
$5,728.31
+$4,728.31 (+473%) by 2050 · US Dollar
Based on the average projected SRPT price of $117.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SRPTwould be worth at today's price.
$1,000 invested in SRPT on Jul 10, 2025 (≈ 52.438386 SRPT) would be worth
$1,076.04
+$76.04 (+7.6%) today · 1.08× · US Dollar
Based on a SRPT entry price of $19.07 vs. today's $20.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.28 | $1,064.32 | +6.4% |
| 1 month ago | $15.11 | $1,358.04 | +35.8% |
| 3 months ago | $21.18 | $968.84 | -3.1% |
| 6 months ago | $21.14 | $970.67 | -2.9% |
| 1 year ago | $19.07 | $1,076.04 | +7.6% |
| All time (5.0y) ago | $70.69 | $290.28 | -71.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SRPT forecast.
Our base-case forecast reaches $41.00 around 2034.
Implied market cap at $41.00: $4.33B
The multi-year forecast shows a measured lift from 2026 onward. The 2026 average price is $19.79 with a range from $15.00 to $27.66 and a neutral sentiment. From 2027 through 2050, the outlook grows increasingly bullish, with 2027 averaging $24.65 and 2028 averaging $25.70, then climbing to $26.72 in 2030 (ROI 35) and advancing to $28.87 in 2031 and $29.36 in 2032.
By 2033 the average is $35.19 and by 2034 it reaches $42.02, with 2035 at $41.29. The longer horizon shows substantial upside, with 2040 averaging $56.58 (ROI 185.9) and 2050 averaging $103.48 (ROI 422.9). These figures reflect a bullish trajectory but are not guarantees and carry inherent uncertainty and risk.
Tap a question to reveal the answer.
Avg price $26.72, with a min $19.40 and a max $39.78. ROI 35, sentiment BULLISH.
Forecast shows neutral in 2026 (avg $19.79, ROI 0) and bullish from 2027 onward, with 2027 avg $24.65 (ROI 24.6) and rising to 2050 with an avg $103.48 (ROI 422.9). These are estimates, not guarantees, and carry risk.
Yes. The 2050 forecast shows an avg of $103.48 and a max of $199.53, indicating potential to exceed $100 on the upper end.
Current price is $19.79 and market cap is $2.09B, with a rank of 2014.
The 30-day range is $16.19 to $24.19. RSI is 70, with SMA50 at $18.02 and SMA200 at $19.72. Support is at $15.00 and resistance at $19.79, with a bullish overall sentiment.
Sarepta Therapeutics, Inc. Community Discussion
0Share your Sarepta Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.